Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002779 | 0.87 | — | — | |
| SCHEMBL2996816 | 0.85 | — | — | |
| SCHEMBL560183 | 0.81 | — | — | |
| SCHEMBL334727 | 0.78 | CTSD (0.33) | CTSD | |
| SCHEMBL2999725 | 0.76 | — | — | |
| SCHEMBL9472583 | 0.76 | CTSD (0.32) | CTSD | |
| SCHEMBL3006783 | 0.70 | CTSD (0.30) | CTSD | |
| SCHEMBL2230540 | 0.69 | CTSD (0.43) | CTSD | |
| Carbon Monoxide SCHEMBL2996926 | 0.69 | CTSD (0.32) | CTSD | |
| Carbon Monoxide SCHEMBL2997964 | 0.69 | CTSD (0.32) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2025-03-13 | — | — | US | claimed |
| EP-4368621-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | Applied Pharmaceutical Science, Inc. (CN) | 2024-05-15 | — | — | EP | claimed |
| WO-2023280073-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | 北京志健金瑞生物医药科技有限公司 | 2023-01-12 | — | — | WO | claimed |
| US-10421703-B2 | Ruthenium-phenol catalysts for transfer hydrogenation reactions | BASF SE (DE) | 2019-09-24 | — | — | US | claimed |
| EP-3113879-B1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | BASF SE (DE) | 2018-04-18 | — | — | EP | claimed |
| US-20180037530-A1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | BASF SE (DE) | 2018-02-08 | — | — | US | claimed |
| US-9790157-B2 | Ruthenium-phenol catalysts and method of preparing menthone from isopulegol | BASF SE (REITSTÖTTER, KINZEBACH & PARTNER) (DE) | 2017-10-17 | — | — | US | claimed |
| US-20170066704-A1 | RUTHENIUM-PHENOL CATALYSTS AND METHOD OF PREPARING MENTHONE FROM ISOPULEGOL | BASF SE (DE) | 2017-03-09 | — | — | US | claimed |
| EP-2915584-A1 | Ruthenium-phenol catalysts for transfer hydrogenation reactions | BASF SE (DE) | 2015-09-09 | — | — | EP | claimed |
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2025-03-13 | — | — | US | disclosed |
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4368621-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | Applied Pharmaceutical Science, Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
| EP-4262803-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4198038-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | Studiengesellschaft Kohle mbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7858814-B2 | Ru-containing polyoxotungstates and process for their preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090318723-A1 | Novel Ru-Containing Polyoxotungstates and Process for Their Preparation | EXXONMOBIL CHEMICAL PATENTS INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009155185-A1 | RUTHENIUM-CONTAINING POLYOXOTUNGSTATES, THEIR PREPARATION AND USE AS CATALYSTS IN THE OXIDATION OF ORGANIC SUBSTRATES | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-5352488-A | Chemical vapor deposition process employing metal pentadienyl complexes | SYRACUSE UNIVERSITY | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066704-A1 | RUTHENIUM-PHENOL CATALYSTS AND METHOD OF PREPARING MENTHONE FROM ISOPULEGOL | HPD, MDH2, PIN4 | CTSD 3571/4885 |
| US-20180037530-A1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | HPD, ICMT, MDH2 | CTSD 3930/4885 |
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | CTSD 1936/4885 |
| US-10421703-B2 | Ruthenium-phenol catalysts for transfer hydrogenation reactions | HPD, ICMT, MDH2 | CTSD 3930/4885 |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | CTSD 2081/4885 |
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | RANBP1, RANBP2, RAN | CTSD 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.